ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.77%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$616M
AUM Growth
+$616M
(+19%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
5.37%
Top 10 Holdings %
Top 10 Hldgs %
49.49%
Holding
239
New
40
Increased
61
Reduced
56
Closed
33
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$52.1M |
| 2 |
Prothena Corp
PRTA
|
$20.5M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 4 |
CytomX Therapeutics
CTMX
|
$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
$6.59M |
Top Sells
| 1 |
RAPT Therapeutics
RAPT
|
$41.5M |
| 2 |
Roivant Sciences
ROIV
|
$17.4M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.63M |
| 4 |
Immunovant
IMVT
|
$6.94M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVR
51
Anteris Technologies Global Corp. Common Stock
AVR
$145M
| $2.01M | 0.31% |
531,515
-1,146,548
| -68% | -$4.35M |
|
|
BPMC
52
DELISTED
Blueprint Medicines
BPMC
| $1.92M | 0.29% |
+15,000
| New | +$1.92M |
|
53
Viking Therapeutics
VKTX
$3.04B
| $1.8M | 0.28% |
67,813
+8,400
| +14% | +$223K |
|
54
Akero Therapeutics
AKRO
$3.74B
| $1.77M | 0.27% |
33,143
-38,000
| -53% | -$2.03M |
|
55
Regeneron Pharmaceuticals
REGN
$61.5B
| $1.76M | 0.27% |
3,361
+2,000
| +147% | +$1.05M |
|
56
Regenxbio
RGNX
$451M
| $1.71M | 0.26% |
207,818
-142,534
| -41% | -$1.17M |
|
57
Dynavax Technologies
DVAX
$1.19B
| $1.69M | 0.26% |
170,000
| – | – |
|
58
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.62M | 0.25% |
34,314
+28,890
| +533% | +$1.36M |
|
|
ORKA
59
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $1.6M | 0.25% |
142,780
+10,000
| +8% | +$112K |
|
60
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $1.56M | 0.24% |
56,540
+15,128
| +37% | +$419K |
|
61
Crinetics Pharmaceuticals
CRNX
$2.92B
| $1.53M | 0.23% |
53,125
| – | – |
|
|
TECX
62
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $1.46M | 0.22% |
73,505
+10,902
| +17% | +$217K |
|
63
Soleno Therapeutics
SLNO
$3.6B
| $1.45M | 0.22% |
17,330
-1,500
| -8% | -$126K |
|
64
Janux Therapeutics
JANX
$1.37B
| $1.43M | 0.22% |
62,088
-91,679
| -60% | -$2.12M |
|
65
Scholar Rock
SRRK
$3.14B
| $1.41M | 0.22% |
39,677
-117,402
| -75% | -$4.16M |
|
66
Astria Therapeutics
ATXS
$349M
| $1.34M | 0.21% |
249,646
-392,044
| -61% | -$2.1M |
|
67
Alkermes
ALKS
$4.78B
| $1.29M | 0.2% |
+45,000
| New | +$1.29M |
|
68
Vir Biotechnology
VIR
$686M
| $1.26M | 0.19% |
250,000
| – | – |
|
69
Agios Pharmaceuticals
AGIO
$2.19B
| $1.19M | 0.18% |
35,900
+8,000
| +29% | +$266K |
|
70
Celldex Therapeutics
CLDX
$1.47B
| $1.17M | 0.18% |
57,466
+42,866
| +294% | +$872K |
|
|
SWTX
71
DELISTED
SpringWorks Therapeutics
SWTX
| $1.13M | 0.17% |
24,082
-183,696
| -88% | -$8.63M |
|
72
Establishment Labs
ESTA
$1.2B
| $1.07M | 0.16% |
25,000
+17,000
| +213% | +$726K |
|
73
Acumen Pharmaceuticals
ABOS
$82.4M
| $1.06M | 0.16% |
916,183
+770,000
| +527% | +$893K |
|
74
Cidara Therapeutics
CDTX
$1.66B
| $1.05M | 0.16% |
21,522
+584
| +3% | +$28.4K |
|
75
Zura Bio
ZURA
$133M
| $1.05M | 0.16% |
997,547
-1,803,637
| -64% | -$1.89M |
|